Christiaan H. Vinkers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christiaan H. Vinkers has a total of 694 co-authors. Here are the top co-authors by number of shared publications:
- Marco Pm Boks
Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands
15 shared publications - Jurjen Justin Luykx
Amsterdam UMC Location University of Amsterdam, Psychiatry, Meibergdreef 9, Amsterdam, The Netherlands
12 shared publications - Joeri K. Tijdink
Department Ethics, Law and Humanities, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
11 shared publications - Willem M. Otte
Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, Member of ERN EpiCARE University Medical Center Utrecht and Utrecht University Utrecht the Netherlands
9 shared publications - Brenda W. J. H. Penninx
Amsterdam UMC
8 shared publications - Elbert Geuze
Ministry of Defence
8 shared publications
Latest Publications
- 9 November 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-3
Should distress and impairment be required for psychiatric diagnosis?
Summary: DSM-style diagnostic criteria often require distress or impairment. We distinguish four questions: why a condition belongs in psychiatric classification, whether an individual meets its criteria, how significant it is for that person and what response is warranted. Distress and impairment should not be universal requirements for individual diagnosis.
- 9 November 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-3
Should distress and impairment be required for psychiatric diagnosis?
Summary: DSM-style diagnostic criteria often require distress or impairment. We distinguish four questions: why a condition belongs in psychiatric classification, whether an individual meets its criteria, how significant it is for that person and what response is warranted. Distress and impairment should not be universal requirements for individual diagnosis.
- 5 October 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 195
Beyond candidate genes: Toward phenotype-specific genetics of cortisol
- 5 October 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 195
Beyond candidate genes: Toward phenotype-specific genetics of cortisol
- Open Access
- 7 September 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 194
Towards a community driven framework for standardized open data in psychoneuroendocrinology: A Delphi consensus study
- 7 September 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 194
Open AccessTowards a community driven framework for standardized open data in psychoneuroendocrinology: A Delphi consensus study
- Open Access
- 3 August 2026
- Published by Center for Open Science in PsyArXiv
Towards a community driven framework for standardized open data in psychoneuroendocrinology: A Delphi consensus study
In psychoneuroendocrinology (PNE), data is valuable due to its high clinical and health-related relevance and resource-intensive data collection yet sharing it openly alongside publications remains uncommon. If shared, data remain highly fragmented and non-standardized, which hinders data reuse and integration across studies. To address this, we formed a consortium and, as a first step, conducted this study using a modified Delphi approach across two survey rounds to inform about important considerations regarding data structure, metadata, subject-level variables, and implementation requirements before a data standard for PNE may be developed. The panel in the final round consisted of 50 responders from the field of PNE. In two online survey rounds, respondents rated their agreement with 84 statements anonymously on a 5-point Likert scale. Consensus (> 70% [dis]agreement) was achieved for 80 items. The results highlight a broad agreement within the PNE community on the need for, and key components of, a standardized data structure, including a balance between flexibility and standardization to allow for adaptability across many use cases as well as comparability. Developing and establishing a standard for PNE data will be a central next step to foster transparency, sustainable use of resources, and the translational potential of our work.
- 3 August 2026
- Published by Center for Open Science in PsyArXiv
Open AccessTowards a community driven framework for standardized open data in psychoneuroendocrinology: A Delphi consensus study
In psychoneuroendocrinology (PNE), data is valuable due to its high clinical and health-related relevance and resource-intensive data collection yet sharing it openly alongside publications remains uncommon. If shared, data remain highly fragmented and non-standardized, which hinders data reuse and integration across studies. To address this, we formed a consortium and, as a first step, conducted this study using a modified Delphi approach across two survey rounds to inform about important considerations regarding data structure, metadata, subject-level variables, and implementation requirements before a data standard for PNE may be developed. The panel in the final round consisted of 50 responders from the field of PNE. In two online survey rounds, respondents rated their agreement with 84 statements anonymously on a 5-point Likert scale. Consensus (> 70% [dis]agreement) was achieved for 80 items. The results highlight a broad agreement within the PNE community on the need for, and key components of, a standardized data structure, including a balance between flexibility and standardization to allow for adaptability across many use cases as well as comparability. Developing and establishing a standard for PNE data will be a central next step to foster transparency, sustainable use of resources, and the translational potential of our work.
- Open Access
- 31 July 2026
- Published by Elsevier in Psychiatry Research
- Vol. 365
Glucocorticoid receptor antagonism in major depressive disorder with childhood trauma: a randomized controlled trial
- 31 July 2026
- Published by Elsevier in Psychiatry Research
- Vol. 365
Open AccessGlucocorticoid receptor antagonism in major depressive disorder with childhood trauma: a randomized controlled trial
- 6 May 2026
- Published by Springer Nature in Nature Mental Health
- Vol. 4 (5) , 766-774
Psychotropic medication use, lifestyle, genetic risk for high BMI and the incidence of cardiovascular disease
- 6 May 2026
- Published by Springer Nature in Nature Mental Health
- Vol. 4 (5) , 766-774
Psychotropic medication use, lifestyle, genetic risk for high BMI and the incidence of cardiovascular disease
- Open Access
- 25 November 2025
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 184, 107703
Functional polygenic risk score of glucocorticoid-dependent regulatory element activity and its relation to clinical and stress-related phenotypes
- 25 November 2025
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 184, 107703
Open AccessFunctional polygenic risk score of glucocorticoid-dependent regulatory element activity and its relation to clinical and stress-related phenotypes
- Open Access
- 24 July 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e68356
Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial
Background: Catatonia is a severe psychomotor syndrome predominantly associated with depressive, bipolar, and psychotic disorders. Untreated catatonia has a 10% mortality rate and may lead to complications such as renal failure, rhabdomyolysis, pneumonia, embolism, and contractures. High doses of the benzodiazepine lorazepam, a gamma-aminobutyric acid (GABA)-A receptor modulator, are the primary pharmacological treatment, enhancing GABA’s inhibitory effect, potentially reducing symptoms of catatonia. However, lorazepam is ineffective in about 25% of cases, leaving electroconvulsive therapy (ECT) as the only well-investigated alternative. Although often effective, ECT may have severe side effects and is not easily accepted among patients and caregivers. Therefore, there is an urgent need for novel therapies for catatonia. Sodium oxybate, a GABA precursor and GABA-B receptor agonist, is a promising alternative treatment based on observational data, but its efficacy has never been thoroughly investigated. Objective: This study aims to evaluate the efficacy and safety of sodium oxybate in treating catatonia unresponsive to lorazepam, while also capturing the natural course and determinants of catatonia through an observational cohort. Methods: The Laborit trial consists of a cohort study and an embedded single-blind randomized controlled trial (RCT). Patients with catatonia admitted to a psychiatric ward may join the study’s cohort, where their clinical characteristics are recorded. Standard care, including lorazepam up to 24 mg/day, will be administered. On day 4, the Bush Francis Catatonia Rating Scale (BFCRS) will be used to measure symptom response. Patients with ≤50% improvement on the BFCRS, compared to the score at start, will be eligible for the trial. A total of 42 patients will be randomly assigned to either the sodium oxybate group, after a 2-day lorazepam reduction period, or the continuation of lorazepam. The primary endpoint is response, measured by the BFCRS score change after 4 days of treatment. A ≥50% reduction in BFCRS will define a responder, who will continue allocated treatment for an additional 10 days, with a secondary endpoint at 14 days. Data will be analyzed using intention-to-treat and per-protocol methods, with chi-square and logistic regression tests to compare group response and remission rates. Results: This study was funded by the Dutch Brain Foundation (Hersenstichting) in December 2020. The study protocol was approved by the Amsterdam UMC Ethics Board on May 22, 2023. As of March 2025, the first 4 participants have been included in the cohort, with no trial participants enrolled yet. Conclusions: If positive, the results of this RCT may pave the way for international catatonia researchers and clinicians to introduce a new pharmacological treatment option for catatonia. Implementation could potentially benefit patients who endure this severe syndrome and present health care professionals with an additional treatment option. Trial Registration: ISRCTN ISRCTN11236443; https://tinyurl.com/4px5s4aa International Registered Report Identifier (IRRID): PRR1-10.2196/68356
- 24 July 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e68356
Open AccessSodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial
Background: Catatonia is a severe psychomotor syndrome predominantly associated with depressive, bipolar, and psychotic disorders. Untreated catatonia has a 10% mortality rate and may lead to complications such as renal failure, rhabdomyolysis, pneumonia, embolism, and contractures. High doses of the benzodiazepine lorazepam, a gamma-aminobutyric acid (GABA)-A receptor modulator, are the primary pharmacological treatment, enhancing GABA’s inhibitory effect, potentially reducing symptoms of catatonia. However, lorazepam is ineffective in about 25% of cases, leaving electroconvulsive therapy (ECT) as the only well-investigated alternative. Although often effective, ECT may have severe side effects and is not easily accepted among patients and caregivers. Therefore, there is an urgent need for novel therapies for catatonia. Sodium oxybate, a GABA precursor and GABA-B receptor agonist, is a promising alternative treatment based on observational data, but its efficacy has never been thoroughly investigated. Objective: This study aims to evaluate the efficacy and safety of sodium oxybate in treating catatonia unresponsive to lorazepam, while also capturing the natural course and determinants of catatonia through an observational cohort. Methods: The Laborit trial consists of a cohort study and an embedded single-blind randomized controlled trial (RCT). Patients with catatonia admitted to a psychiatric ward may join the study’s cohort, where their clinical characteristics are recorded. Standard care, including lorazepam up to 24 mg/day, will be administered. On day 4, the Bush Francis Catatonia Rating Scale (BFCRS) will be used to measure symptom response. Patients with ≤50% improvement on the BFCRS, compared to the score at start, will be eligible for the trial. A total of 42 patients will be randomly assigned to either the sodium oxybate group, after a 2-day lorazepam reduction period, or the continuation of lorazepam. The primary endpoint is response, measured by the BFCRS score change after 4 days of treatment. A ≥50% reduction in BFCRS will define a responder, who will continue allocated treatment for an additional 10 days, with a secondary endpoint at 14 days. Data will be analyzed using intention-to-treat and per-protocol methods, with chi-square and logistic regression tests to compare group response and remission rates. Results: This study was funded by the Dutch Brain Foundation (Hersenstichting) in December 2020. The study protocol was approved by the Amsterdam UMC Ethics Board on May 22, 2023. As of March 2025, the first 4 participants have been included in the cohort, with no trial participants enrolled yet. Conclusions: If positive, the results of this RCT may pave the way for international catatonia researchers and clinicians to introduce a new pharmacological treatment option for catatonia. Implementation could potentially benefit patients who endure this severe syndrome and present health care professionals with an additional treatment option. Trial Registration: ISRCTN ISRCTN11236443; https://tinyurl.com/4px5s4aa International Registered Report Identifier (IRRID): PRR1-10.2196/68356
- Open Access
- 12 November 2024
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 90, 71-76
Environmentally conscious psychopharmacotherapy: Practice recommendations for psychiatrists
- 12 November 2024
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 90, 71-76
Open AccessEnvironmentally conscious psychopharmacotherapy: Practice recommendations for psychiatrists